The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
News|Articles|January 2, 2005
- Pharmaceutical Technology-01-02-2005
- Volume 29
- Issue 1
Comparison of EP "Heavy Metals" Test with USP "Conductivity" Test
Comparative studies of the US Pharmacopeia (645) "Conductivity" and the European Pharmacopeia "Heavy Metals" tests were conducted to demonstrate that the USP method can determine the presence or absence of heavy metals in process water samples.
Advertisement
Articles in this issue
almost 22 years ago
An Overview of the Effect of Moisture on Compaction and Compressionalmost 22 years ago
The Pipeline Crisisalmost 22 years ago
The Outsourcing Advantages in Formulation Developmentalmost 22 years ago
Drug Safety and Access Top Policy Concerns for 2005almost 22 years ago
Patheon Places Big Bet with Mova Acquisitionalmost 22 years ago
January 2005almost 22 years ago
In the Spotlight-January 2005Advertisement
Related to this article
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
FDA draft guidance on individualized genome editing lets BLAs add patient-specific variants without new trials, shifting evidence to CMC assay data.
Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
This week on PharmTech.com, experts discussed E&L suitability standards, rare disease treatment development, sourcing ingredient suppliers, the use of AI in quality control, and more.
Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why AI Model Updates Need Change Control: AAPS PharmSci 360 2026
2
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
3
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
4
AI Formulation: Regulators Want Data
5